Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5112582 | 0.98 | CA12 (0.50) | CA12CA1CA2CA9CYP2D6 | |
| Morpholine SCHEMBL910450 | 0.88 | CYP2D6 (0.44) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL4615811 | 0.81 | — | — | |
| SCHEMBL698257 | 0.80 | CA12 (0.52) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL3422335 | 0.78 | CA12 (0.50) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL2520895 | 0.78 | CA12 (0.50) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL365772 | 0.78 | EPHX2 (0.53) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL3870049 | 0.78 | CA12 (0.50) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL3077421 | 0.78 | CA12 (0.50) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL5199864 | 0.78 | CA12 (0.50) | CA12CA1CA2CA9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116196427-A | Compositions and methods for immune-mediated cancer therapy | 泰克利森有限公司 | 2023-06-02 | — | — | CN | claimed |
| US-20230133566-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | Teclison, Inc. | 2023-05-04 | — | — | US | claimed |
| US-20190070186-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | Teclison, Inc. | 2019-03-07 | — | — | US | claimed |
| EP-2066497-B1 | MANUFACTURING METHODS FOR METAL CLAD LAMINATES | INKTEC CO LTD (KR) | 2018-11-07 | — | — | EP | claimed |
| EP-2013298-B1 | COMPOSITIONS FOR FORMING REFLECTING LAYER HAVING ORGANIC SILVER COMPLEXES,AND METHOD FOR PREPARING REFLECTING LAYER USING SAME | INKTEC CO LTD (KR) | 2018-06-27 | — | — | EP | claimed |
| EP-2052043-B1 | PROCESS FOR PREPARATION OF SILVER NANOPARTICLES, AND THE COMPOSITIONS OF SILVER INK CONTAINING THE SAME | INKTEC CO LTD (KR) | 2016-10-12 | — | — | EP | claimed |
| EP-1846422-B1 | ORGANIC SILVER COMPLEXES, THEIR PREPARATION METHODS AND THEIR METHODS FOR FORMING THIN LAYERS | INKTEC CO LTD (KR) | 2016-04-13 | — | — | EP | claimed |
| US-9090785-B2 | Silver ink composition | INKTEC CO., LTD. (KR) | 2015-07-28 | — | — | US | claimed |
| EP-2752470-A1 | Process for preparation of silver nanoparticles, and the compositions of silver ink containing the same | Inktec Co., Ltd. (KR) | 2014-07-09 | — | — | EP | claimed |
| US-20140065139-A1 | Induction of Tumor Hypoxia for Cancer Therapy | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-03-06 | — | — | US | claimed |
| US-20120087913-A1 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY | VIRGINIA COMMONWEALTH UNIVERSITY | 2012-04-12 | — | — | US | claimed |
| US-20100189901-A1 | PROCESS FOR PREPARATION OF SILVER NANOPARTICLES, AND THE COMPOSITIONS OF SILVER INK CONTAINING THE SAME | INKTEC CO., LTD. (KR) | 2010-07-29 | — | — | US | claimed |
| WO-2009126705-A2 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2009-10-15 | — | — | WO | claimed |
| EP-2052043-A1 | PROCESS FOR PREPARATION OF SILVER NANOPARTICLES, AND THE COMPOSITIONS OF SILVER INK CONTAINING THE SAME | Inktec Co., Ltd. (KR) | 2009-04-29 | — | — | EP | claimed |
| WO-2008018718-A1 | PROCESS FOR PREPARATION OF SILVER NANOPARTICLES, AND THE COMPOSITIONS OF SILVER INK CONTAINING THE SAME | INKTEC CO., LTD. (KR) | 2008-02-14 | — | — | WO | claimed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | claimed |
| WO-1997038114-A1 | PUROMYCIN-SENSITIVE AMINOPEPTIDASES | NOVARTIS AG (CH) | 1997-10-16 | — | — | WO | claimed |
| WO-1996005298-A1 | ANTITUMOR ANTISENSE OLIGONUCLEOTIDES | CIBA-GEIGY AG (CH) | 1996-02-22 | — | — | WO | claimed |
| EP-0088377-B1 | CARBAMATE AND CARBONATE SALTS OF TERTIARY AMINES | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1987-04-22 | — | — | EP | claimed |
| US-4542214-A | DELAYED ACTION POLYURETHANE CATALYSTS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1985-09-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189901-A1 | PROCESS FOR PREPARATION OF SILVER NANOPARTICLES, AND THE COMPOSITIONS OF SILVER INK CONTAINING THE SAME | NRAS, C1R, BAP1 | CA12 725/4885CA1 260/4885CA2 156/4885 |
| US-20230133566-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | CD47, HIF1AN, HIF1A | CA12 35/4885CA1 39/4885CA2 89/4885 |
| US-20140065139-A1 | Induction of Tumor Hypoxia for Cancer Therapy | HIF1A, HIF1AN, HYOU1 | CA12 91/4885CA1 28/4885CA2 20/4885 |
| US-20120087913-A1 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY | HIF1A, HIF1AN, HYOU1 | CA12 91/4885CA1 28/4885CA2 20/4885 |
| US-20190070186-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | CD47, HIF1AN, HIF1A | CA12 35/4885CA1 39/4885CA2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.